 |
VasoMedical to Showcase BIOX® Products at the 71st China International Medical Equipment Fair |
MobiCare® Revolutionary Patient Centric Monitoring to be Highlighted
WESTBURY, N.Y. – April 2, 2014 – VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the BIOX Instruments Co. Ltd., a subsidiary of VasoMedical, will attend and exhibit at the 71st China International Medical Equipment Fair (CMEF) from April 17-20, 2014 in Shenzhen, China.
The China International Medical Equipment Fair, founded in 1979, is held twice a year during the spring and autumn seasons. It has become the second largest exhibition of medical equipment, related products and services in the world, attracting over 2,600 exhibitors and over 82,000 attendees from more than 100 countries. With over 5,400 booths the exhibition features products from across the medical device industry, including medical imaging, in vitro diagnosis, electronics, optics, first aid, rehabilitation, nursing, medical information technology and outsourcing services, among many others. BIOX has been participating in both spring and autumn events for 18 consecutive years and under VasoMedical brand since 2012.
VasoMedical-BIOX will be located at Booth #H1D02 in the Shenzhen Convention and Exhibition Center. It will present the BIOX line of ambulatory monitoring systems including ECG Holter monitors, ambulatory blood pressure monitors (ABPM), analysis and reporting software, as well as many OEM modules for EEG (electroencephalography), oximeter, etc. VasoMedical's EECP® Therapy will also be featured in the show.
“BIOX Instruments recently received Chinese FDA approval to market its innovative MobiCareTM wireless vital signs patient monitors and CMEF presents us with a great stage to increase awareness in the market about the new product and actively begin to sell it along side our current product line”, said Qiuming Shen, president of BIOX Instruments. He continued, “We also look forward to this show in order to meet with customers, healthcare companies and other industry leaders as we plan and design products to meet the future needs of the global healthcare market. Since BIOX is also an OEM manufacturer, this meeting helps us to showcase our company's abilities and create opportunities to work with other medical device companies who wish to benefit from our expertise and international experience. With participation from our colleagues from New York, we will take the opportunity to also promote VasoMedical's EECP® Therapy, as well as BIOX products to Chinese and international customers.”
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through four wholly owned subsidiaries: VasoMedical Solutions, Inc., VasoMedical Global Corp., Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, and VasoHealthcare IT Corp. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments; and VasoHealthcare IT is a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support.. Additional information is available on the Company's website at www.vasomedical.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220/212-896-1273
swolf@kcsa.com / aherweg@kcsa.com